Cell BiologybioRxivPreprint
Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs
Christos M. Kougentakis, Matthew J. Shurtleff, Rachel M. Lieser…·Nicholas A. Lind
This paper introduces cataLYTACs, a new therapeutic modality that efficiently and durably degrades circulating proteins like IgE in vitro and in vivo, outperforming traditional inhibitors.